| A Single and Multiple Dose of Rodatristat Ethyl in Healthy Adult Subjects to Evaluate the Effect of Food and Safety (NCT05684640) | Altavant Sciences GmbH | 2022-09-29 |
| F-Tryptophan PET/CT in Human Cancers (NCT05556473) | Barbara Ann Karmanos Cancer Institute | 2022-09-29 |
| A Study Comparing Two Forms of Tafamidis Without Food and the Amount of Tafamidis in the Blood With Food (NCT05498701) | Pfizer | 2022-09-29 |
| Double-blind, Randomized, Placebo-controlled Study of the Safety, Tolerability and Pharmacokinetics of Ascending Doses of XC243 After Single and Multiple Oral Administration in Healthy Volunteers. (NCT05628116) | PHARMENTERPRISES LLC | 2022-09-28 |
| A Study of 68Gallium PSMA-PET/CT Scans in People With Bladder Cancer or Skin Cancer (NCT05562791) | Memorial Sloan Kettering Cancer Center | 2022-09-28 |
| ABC008 in Subjects With T-cell Large Granular Lymphocytic Leukemia (T-LGLL) (NCT05532722) | Abcuro, Inc. | 2022-09-28 |
| Treatment of Pneumocystis in COPD (the TOPIC Study) (NCT05418777) | Corewell Health East | 2022-09-28 |
| Study to Evaluate a 25-Valent Pneumococcal Conjugate Vaccine (NCT05540028) | Inventprise Inc. | 2022-09-28 |
| Relative Bioavailability Study of Nirmatrelvir/Ritonavir Oral Powder Relative to the Commercial Tablets and Estimation of the Effect of Food on Bioavailability of the Nirmatrelvir/Ritonavir Oral Powder in Healthy Participants. (NCT05544786) | Pfizer | 2022-09-28 |
| Treatment of Advanced Solid Tumors With Neo-T(GI-NeoT-02) (NCT05798546) | BGI, China | 2022-09-28 |
| To Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Disitamab Vedotin Combined With RC98 in the Treatment of Subjects With HER2-expressing Locally Advanced or Metastatic Gastric Cancer (Including AEG) (NCT05514158) | RemeGen Co., Ltd. | 2022-09-28 |
| Study to Evaluate the Relative Bioavailability of Two Risankizumab Drug Product Presentations in Healthy Volunteers. (NCT05567029) | AbbVie | 2022-09-28 |
| A Study to Assess the Safety and Tolerability of BMS-986322 in Healthy Participants of Japanese Descent (NCT05546151) | Bristol-Myers Squibb | 2022-09-28 |
| A Study in People With Colorectal Cancer to Test Whether Ezabenlimab or Pembrolizumab in Combination With BI 765063 Lead to Side Effects or Delays in Surgery (NCT05446129) | Boehringer Ingelheim | 2022-09-27 |
| A Study to Assess How Food Affects the Safety and Pharmacokinetics of Galicaftor and Navocaftor (NCT05538585) | AbbVie | 2022-09-27 |
| Study to Evaluate Multiple Ascending Dose and Multi-Dose of DT-216 in Adult Patients With Friedreich Ataxia (NCT05573698) | Design Therapeutics, Inc. | 2022-09-27 |
| OPT101 in Type 1 Diabetes Patients (NCT05428943) | Op-T LLC | 2022-09-27 |
| Evaluate the Safety and Pharmacokinetic Profile of ETR028 and ETR029 in Healthy Adult Subjects (NCT05572190) | Elysium Therapeutics, Inc. | 2022-09-27 |
| Phase 1/2 Study of ISB 1442 in Relapsed/Refractory Multiple Myeloma (NCT05427812) | Ichnos Sciences SA | 2022-09-27 |
| Phase 1b/2 Study to Evaluate ABT-101 in Solid Tumor and NSCLC Patients (NCT05532696) | Anbogen Therapeutics, Inc. | 2022-09-27 |
| A Study in Healthy Men to Test How Different Doses of BI 3032950 Are Tolerated (NCT05518708) | Boehringer Ingelheim | 2022-09-27 |
| A Randomized, Open-label, Three-way Crossover Study to Evaluate the Relative Bioavailability of 200 Mg Cenobamate Administered Orally (NCT05572255) | SK Life Science, Inc. | 2022-09-27 |
| KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer (NCT05483491) | Christian Hinrichs | 2022-09-26 |
| XW014 in Healthy Subjects and Patients With Type 2 Diabetes Mellitus (T2DM) (NCT05579314) | Sciwind Biosciences USA Co., Ltd. | 2022-09-26 |
| A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer (NCT05483868) | Aura Biosciences | 2022-09-26 |
| Effect of Food on Pharmacokinetics of MY008211A Tablets in Healthy Adult Subjects (NCT05828485) | Wuhan Createrna Science and Technology Co., Ltd | 2022-09-26 |
| A Study of MGD020 Alone or Combined With MGD014 in Persons With HIV-1 on Antiretroviral Therapy (NCT05261191) | MacroGenics | 2022-09-26 |
| PK Study of Xevinapant (Debio 1143) in Healthy East Asian Participants (NCT05519540) | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | 2022-09-26 |
| A Study of GNC-038 Injection in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma (NCT05623982) | Sichuan Baili Pharmaceutical Co., Ltd. | 2022-09-26 |
| UTAA06 Injection in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia (NCT05731219) | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | 2022-09-26 |
| Study of MK-4464 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced/Metastatic Solid Tumors (MK-4464-001) (NCT05514444) | Merck Sharp & Dohme LLC | 2022-09-25 |
| Evaluation the Effects of Various Treatments on RZL-012-Induced Adverse Events (NCT05476679) | Raziel Therapeutics Ltd. | 2022-09-25 |
| A Phase 1b/2 Study of YL-13027 Combined With Sintilimab in Patients With Advanced Solid Tumors (NCT05457517) | Shanghai YingLi Pharmaceutical Co. Ltd. | 2022-09-24 |
| A Study to Evaluate the Safety and Pharmacokinetics of Ceralasertib in Combination With Durvalumab in Chinese Patients With Advanced Solid Tumours (NCT05514132) | AstraZeneca | 2022-09-23 |
| A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression (NCT05325866) | Amgen | 2022-09-23 |
| Clinical Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-386 in Healthy Volunteers Under Fasting Conditions (NCT05552495) | Chong Kun Dang Pharmaceutical | 2022-09-23 |
| Pharmacokinetics of Irbesartan/Amlodipine High FDC and Co-administration of Irbesartan and Amlodipine High in Healthy Volunteers (NCT05688098) | Handok Inc. | 2022-09-23 |
| A Trial of HBM9378 in Healthy Chinese Subjects (NCT05790694) | Harbour BioMed (Guangzhou) Co. Ltd. | 2022-09-23 |
| Evaluate the Safety and Immunogenicity of a 9-valent HPV Vaccine in Chinese Healthy Male Aged 9-45 Year-old (NCT05518201) | Shanghai Bovax Biotechnology Co., Ltd. | 2022-09-23 |
| Atezolizumab and Cabozantinib for the Treatment of Recurrent Glioblastoma (NCT05039281) | M.D. Anderson Cancer Center | 2022-09-23 |
| RP-3500 and Olaparib in DNA Damage Repair Pathway Deficient Relapsed/Refractory Chronic Lymphocytic Leukemia (NCT05405309) | University of Utah | 2022-09-23 |
| Enoxolone in Major Depression - Biomarker-outcome Relationship (NCT05570110) | Philipps University Marburg | 2022-09-23 |
| Effects of Different Doses of Vitamin D on Cancer-related Cognitive Impairment in Patients With Gastrointestinal Tumors (NCT05552729) | Yangzhou University | 2022-09-22 |
| A Study to Evaluate the Pharmacokinetic Drug-drug Interactions Between VX-548, Midazolam, and Digoxin (NCT05541471) | Vertex Pharmaceuticals Incorporated | 2022-09-22 |
| A Study to Investigate The Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7486967 in Participants With Early Idiopathic Parkinson's Disease. (NCT05924243) | Hoffmann-La Roche | 2022-09-22 |
| Pamiparib Plus Surufatinib in Patients With Platinum-resistant Ovarian Cancer (NCT05494580) | Sun Yat-sen University | 2022-09-22 |
| GS3-007a Oral Solution in Healthy Subjects (NCT05611281) | Changchun GeneScience Pharmaceutical Co., Ltd. | 2022-09-22 |
| Refining Cough Skill Training in Parkinson's Disease and Dysphagia (NCT05700838) | Teachers College, Columbia University | 2022-09-21 |
| Safety and Immunogenicity of IVX-A12 in Healthy Older Adults (NCT05664334) | Icosavax, Inc. | 2022-09-21 |
| A Study of TH-SC01 in the Treatment of Radiation-induced Rectal Injury (NCT05939778) | Jinling Hospital, China | 2022-09-21 |
| Phase I Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation (NCT05533463) | Jiangsu HengRui Medicine Co., Ltd. | 2022-09-21 |
| VIC-1911 Combined With Osimertinib for EGFR -Mutant Non-small Cell Lung Cancer (NCT05489731) | Jiesi Yingda Pharmaceutical Technology (Suzhou) Co., Ltd. | 2022-09-21 |
| Drug-drug Interactions Between DWP14012 and DWC202202 in Healthy Subjects (NCT05574374) | Daewoong Pharmaceutical Co. LTD. | 2022-09-21 |
| Effect of Hepatic Impairment on the Pharmacokinetics and Safety of VIR-2218 and VIR-3434 (NCT05484206) | Vir Biotechnology, Inc. | 2022-09-21 |
| CXCR4 Modified Anti-BCMA CAR T Cells for Multiple Myeloma (NCT04727008) | Sichuan University | 2022-09-21 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of K-757 in Healthy Overweight/Obese Volunteers (NCT05900531) | Kallyope Inc. | 2022-09-21 |
| A Study to Evaluate the Safety, Tolerability, PK and PD of Intracerebroventricular GC1123 in Patients with MPS Ⅱ (NCT05422482) | GC Biopharma Corp | 2022-09-20 |
| Multi-System Analysis of Opioid Receptor Binding (NCT05528848) | University of Pennsylvania | 2022-09-20 |
| A Study to Assess the Pharmacokinetics and Safety of Co-administered Oral Galicaftor, Navocaftor, and ABBV-576 in Healthy Adults for the Treatment of Cystic Fibrosis (NCT05530278) | AbbVie | 2022-09-20 |
| Dose Escalation and Expansion Study of SAR444200-based Regimen in Adult Participants With Advanced Solid Tumors (NCT05450562) | Sanofi | 2022-09-20 |
| Assess the Safety, Tolerability, and Pharmacokinetics of AZD6234 Following Single Ascending Dose Administration to Healthy Subjects Who Are Overweight or Obese (NCT05511025) | AstraZeneca | 2022-09-20 |
| A Study of Duvelisib Combined With SG001 Injection in Patient With Advanced Solid Tumors (NCT05508659) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2022-09-20 |
| Evaluate the Pharmacokinetics of BAT2606 Injection in Healthy Chinese Male Subjects (NCT05576454) | Bio-Thera Solutions | 2022-09-20 |
| A Study of MK-2214 in Adults With Mild Cognitive Impairment or Mild-to-Moderate Alzheimer's Disease (MK-2214-002) (NCT05466422) | Merck Sharp & Dohme LLC | 2022-09-20 |
| Chidamide + Celecoxib in Advanced Metastatic Colorectal Cancer (CCmCC) (NCT05281276) | Taipei Medical University Shuang Ho Hospital | 2022-09-20 |
| RC48-ADC Combined With S-1 for First-line Treatment of Advanced Gastroesophageal Adenocarcinoma With Moderate Expression of HER2 (NCT05403242) | Chinese PLA General Hospital | 2022-09-20 |
| Efficacy and Safety of IBI351 in Combination With Chemotherapy in Advanced Non-squamous Non-small Cell Lung Cancer Subjects With KRAS G12C Mutation (NCT05504278) | Innovent Biologics (Suzhou) Co. Ltd. | 2022-09-20 |
| A Study to Learn How Safe Study Drug BAY2413555 is, How it Affects the Body, and How it Moves Into, Through, and Out of the Body Over 4 Weeks of Use in Participants With Heart Failure and Implanted Cardiac Defibrillator or Cardiac Resynchronization Devices (ICD/CRT) (NCT05532046) | Bayer | 2022-09-20 |
| A Phase 1, Open Label Study of Intravenous GSK3745417 to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Determine RP2D & Schedule in Participants With Relapsed or Refractory Myeloid Malignancies Including AML and HR MDS (NCT05424380) | GlaxoSmithKline | 2022-09-20 |
| A Pharmacokinetic Study of SHR8554 Injection in the Population With Renal Insufficiency and Healthy Participants (NCT07189962) | Jiangsu HengRui Medicine Co., Ltd. | 2022-09-20 |
| Trial of PXS-5505 Combined With First Line Atezolizumab Plus Bevacizumab For Treating Patients With Unresectable Hepatocellular Carcinoma (NCT05109052) | University of Rochester | 2022-09-20 |
| Study to Investigate the Safety of the Transplantation of Human Glial Restricted Progenitor Cells Into Subjects With Transverse Myelitis (NCT03887273) | Q Therapeutics, Inc. | 2022-09-20 |
| Autologous HuCART19 T Cells Manufactured Using the CliniMACS Prodigy Platform for Pediatric B-ALL (huCART19 Prodigy) (NCT05480449) | Stephan Grupp MD PhD | 2022-09-20 |
| SM-1 Combined With Temozolomide in Subjects With Refractory or Recurrent High-Grade Gliomas (NCT07635173) | Shenzhen Zhenxing Medical Technology Co., Ltd | 2022-09-19 |
| Pressurized Intraperitoneal Aerosolized Nab-Paclitaxel in Combination With Gemcitabine and Cisplatin for the Treatment of Biliary Tract Cancer Patients With Peritoneal Metastases (NCT05285358) | City of Hope Medical Center | 2022-09-19 |
| Single Dose Study to Evaluate Dose-proportionality of Vortioxetine Hemihydrobromide Orally Disintegrating Tablets (NCT05416762) | Seasons Biotechnology (Taizhou) Co., Ltd. | 2022-09-19 |
| A Study to Test the Effects of Itraconazole and Carbamazepine on OPC-167832 in Healthy Men and Women (NCT07542847) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2022-09-19 |
| Study to Compare the Level of Elafibranor in Blood After Repeat Administration in Japanese and Non-Asian Healthy Participants (NCT05543369) | Ipsen | 2022-09-19 |
| Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors (NCT05462717) | Revolution Medicines, Inc. | 2022-09-19 |
| Seleno-L Methionine (SLM)-Axitinib-Pembrolizumab (NCT05363631) | Mohammed Milhem | 2022-09-19 |
| Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer (NCT05172245) | National Cancer Institute (NCI) | 2022-09-19 |
| A Study in Healthy Men to Test How BI 690517 is Taken up and Handled by the Body (NCT05515588) | Boehringer Ingelheim | 2022-09-19 |
| Study of the Safety, Tolerability, Pharmacokinetics and Biomarker of DONQ52 in Celiac Disease Patients (NCT05425446) | Chugai Pharmaceutical | 2022-09-19 |
| Doxycycline in Cutaneous Schwannoma (NF2) (NCT05521048) | Massachusetts Eye and Ear Infirmary | 2022-09-19 |
| Clinical Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-387 in Healthy Volunteers Under Fed Conditions (NCT06399068) | Chong Kun Dang Pharmaceutical | 2022-09-19 |
| Food Effect Bioavailability Study of Vortioxetine Hemihydrobromide Orally Disintegrating Tablets (NCT05416957) | Seasons Biotechnology (Taizhou) Co., Ltd. | 2022-09-18 |
| NAD-brain: a Pharmacokinetic Study of NAD Replenishment Therapy (NCT05698771) | Haukeland University Hospital | 2022-09-17 |
| A Phase 1 Dose Escalation Study of VX-708 in Healthy Participants (NCT05518734) | Vertex Pharmaceuticals Incorporated | 2022-09-17 |
| First-in-human (FIH) Phase I Trial of BS-006 in Cervical Cancer (NCT05393440) | Zhongnan Hospital | 2022-09-16 |
| A First in Human Study of AUR 103 Calcium to Evaluate Safety, Pharmacokinetics and Pharmacodynamics (NCT05607199) | Aurigene Discovery Technologies Limited | 2022-09-16 |
| Safety and Efficacy Study of STI-1558 in Healthy Adults and SARS-CoV-2-Positive Patients (NCT05523739) | Zhejiang ACEA Pharmaceutical Co. Ltd. | 2022-09-16 |
| A Trial to Evaluate the Effect of LEO 152020 on the Heart of Healthy People (NCT05508776) | JW Pharmaceutical | 2022-09-16 |
| Clinical Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-387 in Healthy Volunteers Under Fasting Conditions (NCT06399055) | Chong Kun Dang Pharmaceutical | 2022-09-16 |
| Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01) (NCT05519449) | Janux Therapeutics | 2022-09-15 |
| A Trial of Injectable SHR-A1811 in Combination With Pyrotinib or SHR-1316 in Subjects With Advanced Non-small Cell Lung Cancer (NCT05482568) | Jiangsu HengRui Medicine Co., Ltd. | 2022-09-15 |
| Safety and Pharmacokinetics of HU6 (NCT05433506) | Rivus Pharmaceuticals, Inc. | 2022-09-15 |
| Virtual Reality-Reward Training for Anhedonia (NCT05342077) | University of California, Los Angeles | 2022-09-15 |
| A Study to Evaluate the Relative Bioavailability of a Fixed-dose Combination Tablet of VX-121/Tezacaftor/Deutivacaftor (NCT05535959) | Vertex Pharmaceuticals Incorporated | 2022-09-15 |
| A Trial to Learn if a COVID-19 Therapeutic is Safe and Well Tolerated, and How it Works in the Body of Healthy Adult Participants (NCT05505448) | Regeneron Pharmaceuticals | 2022-09-15 |
| Mesenchymal Stem Cells for The Treatment of Knee Osteoarthritis (KOA). (NCT04893174) | Meridigen Biotech Co., Ltd. | 2022-09-15 |